Tolerogenic dendritic cells and their potential applications

Immunology

Volumn 132, Issue 3, 2011, Pages 307-314

  Hu, Jim ^a,b   Wan, Yonghong ^c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Dendritic cells; Immune responses; T cells; Therapy; Tolerance

Indexed keywords

ANTIGEN; CELL SURFACE MARKER;

ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; CELL FUNCTION; CELL THERAPY; DENDRITIC CELL; GENE THERAPY; HUMAN; HYPERSENSITIVITY; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIFFERENTIATION; DENDRITIC CELLS; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE;

EID: 79251646395     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2010.03396.x     Document Type: Review

References (123)

1. Steinman RM. Dendritic cells: understanding immunogenicity. Eur J Immunol 2007; 37(Suppl. 1):S53-60.
2. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711.
3. Bar-On L, Jung S. Defining dendritic cells by conditional and constitutive cell ablation. Immunol Rev 2010; 234:76-89.
4. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327:656-61.
5. Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol Rev 2010; 234:45-54.
6. + dendritic cells to the marginal zone of mouse spleen. Proc Natl Acad Sci U S A 2009; 106:1524-9.
7. + DCs. J Exp Med 2009; 206:3115-30.
8. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003; 19:225-34.
9. Corcoran L, Ferrero I, Vremec D et al. The lymphoid past of mouse plasmacytoid cells and thymic dendritic cells. J Immunol 2003; 170:4926-32.
10. Tam MA, Wick MJ. Dendritic cells and immunity to Listeria: TipDCs are a new recruit. Trends Immunol 2004; 25:335-9.
11. Aldridge JR Jr, Moseley CE, Boltz DA et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A 2009; 106:5306-11.
12. Serbina NV, Salazar-Mather TP, Biron CA, Kuziel WA, Pamer EG. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 2003; 19:59-70.
13. Dunay IR, Damatta RA, Fux B, Presti R, Greco S, Colonna M, Sibley LD. Gr1(+) inflammatory monocytes are required for mucosal resistance to the pathogen Toxoplasma gondii. Immunity 2008; 29:306-17.
14. Steiner G, Wolff K, Pehamberger H, Stingl G. Epidermal cells as accessory cells in the generation of allo-reactive and hapten-specific cytotoxic T lymphocyte (CTL) responses. J Immunol 1985; 134:736-41.
15. Schuler G, Romani N, Steinman RM. A comparison of murine epidermal Langerhans cells with spleen dendritic cells. J Invest Dermatol 1985; 85:99s-106s.
16. Schuler G, Steinman RM. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med 1985; 161:526-46.
17. Inaba K, Schuler G, Witmer MD, Valinksy J, Atassi B, Steinman RM. Immunologic properties of purified epidermal Langerhans cells. Distinct requirements for stimulation of unprimed and sensitized T lymphocytes. J Exp Med 1986; 164:605-13.
18. Witmer-Pack MD, Olivier W, Valinsky J, Schuler G, Steinman RM. Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med 1987; 166:1484-98.
19. Chorro L, Sarde A, Li M et al. Langerhans cell (LC) proliferation mediates neonatal development, homeostasis, and inflammation-associated expansion of the epidermal LC network. J Exp Med 2009; 206:3089-100.
20. Ginhoux F, Merad M. Ontogeny and homeostasis of Langerhans cells. Immunol Cell Biol 2010; 88:387-92.
21. Steinman RM, Witmer MD. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci U S A 1978; 75:5132-6.
22. Steinman RM, Gutchinov B, Witmer MD, Nussenzweig MC. Dendritic cells are the principal stimulators of the primary mixed leukocyte reaction in mice. J Exp Med 1983; 157:613-27.
23. Liu K, Waskow C, Liu X, Yao K, Hoh J, Nussenzweig M. Origin of dendritic cells in peripheral lymphoid organs of mice. Nat Immunol 2007; 8:578-83.
24. Waskow C, Liu K, Darrasse-Jeze G et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol 2008; 9:676-83.
25. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6:1133-41.
26. Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol 2006; 6:329-33.
27. Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol 2009; 9:833-44.
28. Bonasio R, Scimone ML, Schaerli P, Grabie N, Lichtman AH, von Andrian UH. Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus. Nat Immunol 2006; 7:1092-100.
29. Proietto AI, van Dommelen S, Zhou P et al. Dendritic cells in the thymus contribute to T-regulatory cell induction. Proc Natl Acad Sci U S A 2008; 105:19869-74.
30. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6:345-52.
31. + T cells. J Exp Med 1997; 186:239-45.
32. + T cell tolerance. Immunity 2003; 18:713-20.
33. Hawiger D, Inaba K, Dorsett Y et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194:769-79.
34. + regulatory T cells: more of the same or a division of labor? Immunity 2009; 30:626-35.
35. Saurer L, Mueller C. T cell-mediated immunoregulation in the gastrointestinal tract. Allergy 2009; 64:505-19.
36. Hadeiba H, Sato T, Habtezion A, Oderup C, Pan J, Butcher EC. CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease. Nat Immunol 2008; 9:1253-60.
37. Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 2002; 196:1091-7.
38. Lechler R, Chai JG, Marelli-Berg F, Lombardi G. The contributions of T-cell anergy to peripheral T-cell tolerance. Immunology 2001; 103:262-9.
39. - conventional CD4 T cells and induction of CD4 T-cell anergy. Eur J Immunol 2009; 39:1078-87.
40. Qi H, Egen JG, Huang AY, Germain RN. Extrafollicular activation of lymph node B cells by antigen-bearing dendritic cells. Science 2006; 312:1672-6.
41. Bergtold A, Desai DD, Gavhane A, Clynes R. Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 2005; 23:503-14.
42. Koka R, Burkett P, Chien M, Chai S, Boone DL, Ma A. Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells. J Immunol 2004; 173:3594-8.
43. Hochweller K, Striegler J, Hammerling GJ, Garbi N. A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells. Eur J Immunol 2008; 38:2776-83.
44. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S, Ma A. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998; 9:669-76.
45. Kennedy MK, Glaccum M, Brown SN et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191:771-80.
46. Plaks V, Birnberg T, Berkutzki T et al. Uterine DCs are crucial for decidua formation during embryo implantation in mice. J Clin Invest 2008; 118:3954-65.
47. Inaba K, Steinman RM, Pack MW, Aya H, Inaba M, Sudo T, Wolpe S, Schuler G. Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med 1992; 175:1157-67.
48. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176:1693-702.
49. Goxe B, Latour N, Chokri M, Abastado JP, Salcedo M. Simplified method to generate large quantities of dendritic cells suitable for clinical applications. Immunol Invest 2000; 29:319-36.
50. Thomson AW. Tolerogenic dendritic cells: all present and correct? Am J Transplant 2010; 10:214-9.
51. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117:1195-203.
52. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801.
53. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987-95.
54. Martin-Fontecha A, Lanzavecchia A, Sallusto F. Dendritic cell migration to peripheral lymph nodes. Handb Exp Pharmacol 2009; 188, 31-49.
55. Baumjohann D, Hess A, Budinsky L, Brune K, Schuler G, Lutz MB. In vivo magnetic resonance imaging of dendritic cell migration into the draining lymph nodes of mice. Eur J Immunol 2006; 36:2544-55.
56. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor-α. J Exp Med 1994; 179:1109-18.
57. - dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J Immunol 2005; 174:6592-7.
58. Steinman RM, Hawiger D, Liu K et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci 2003; 987:15-25.
59. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006; 108:1435-40.
60. + regulatory T cells in vivo: therapeutic applications in autoimmunity and transplantation. Ann N Y Acad Sci 2006; 1070:190-5.
61. + regulatory T cells. Proc Natl Acad Sci USA 2010; 107:6424-9.
62. Farquhar CA, Paterson AM, Cobbold SP et al. Tolerogenicity is not an absolute property of a dendritic cell. Eur J Immunol 2010; 40:1728-37.
63. Kalinski P. Dendritic cells in immunotherapy of established cancer: roles of signals 1, 2, 3 and 4. Curr Opin Investig Drugs 2009; 10:526-35.
64. Berger TG, Schulze-Koops H, Schafer M, Muller E, Lutz MB. Immature and maturation-resistant human dendritic cells generated from bone marrow require two stimulations to induce T cell anergy in vitro. PLoS ONE 2009; 4:e6645.
65. Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001; 166:3499-505.
66. Lu L, Lee WC, Takayama T, Qian S, Gambotto A, Robbins PD, Thomson AW. Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-β, and CTLA4Ig). J Leukoc Biol 1999; 66:293-6.
67. + regulatory T cells from peripheral Foxp3 precursors. Blood 2007; 110:4293-302.
68. + regulatory T cells. J Immunol 2009; 182:2795-807.
69. Lee WC, Qiani S, Wan Y et al. Contrasting effects of myeloid dendritic cells transduced with an adenoviral vector encoding interleukin-10 on organ allograft and tumour rejection. Immunology 2000; 101:233-41.
70. + Tr cells. Blood 2005; 105:1162-9.
71. Kim SH, Bianco N, Menon R, Lechman ER, Shufesky WJ, Morelli AE, Robbins PD. Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Mol Ther 2006; 13:289-300.
72. Bohana-Kashtan O, Civin CI. Fas ligand as a tool for immunosuppression and generation of immune tolerance. Stem Cells 2004; 22:908-24.
73. Yang DF, Qiu WH, Zhu HF, Lei P, Wen X, Dai H, Zhou W, Shen GX. CTLA4-Ig-modified dendritic cells inhibit lymphocyte-mediated alloimmune responses and prolong the islet graft survival in mice. Transpl Immunol 2008; 19:197-201.
74. Bianco NR, Kim SH, Ruffner MA, Robbins PD. Therapeutic effect of exosomes from indoleamine 2, 3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheum 2009; 60:380-9.
75. Hirata S, Senju S, Matsuyoshi H, Fukuma D, Uemura Y, Nishimura Y. Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand. J Immunol 2005; 174:1888-97.
76. Hill JA, Ichim TE, Kusznieruk KP et al. Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol 2003; 171:691-6.
77. Lee JI, Ganster RW, Geller DA, Burckart GJ, Thomson AW, Lu L. Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor-κB. Transplantation 1999; 68:1255-63.
78. Yang J, Bernier SM, Ichim TE et al. LF15-0195 generates tolerogenic dendritic cells by suppression of NF-κB signaling through inhibition of IKK activity. J Leukoc Biol 2003; 74:438-47.
79. Unger WW, Laban S, Kleijwegt FS, van der Slik AR, Roep BO. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol 2009; 39:3147-59.
80. Pothoven KL, Kheradmand T, Yang Q, Houlihan JL, Zhang H, Degutes M, Miller SD, Luo X. Rapamycin-conditioned donor dendritic cells differentiate CD4CD25Foxp3 T cells in vitro with TGF-β1 for islet transplantation. Am J Transplant 2010; 10:1774-84.
81. Raimondi G, Sumpter TL, Matta BM, Pillai M, Corbitt N, Vodovotz Y, Wang Z, Thomson AW. Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. J Immunol 2010; 184:624-36.
82. + T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178:7018-31.
83. van de Laar L, Buitenhuis M, Wensveen FM, Janssen HL, Coffer PJ, Woltman AM. Human CD34-derived myeloid dendritic cell development requires intact phosphatidylinositol 3-kinase-protein kinase B-mammalian target of rapamycin signaling. J Immunol 2010; 184:6600-11.
84. Woltman AM, de Fijter JW, Kamerling SW, van Der Kooij SW, Paul LC, Daha MR, van Kooten C. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 2001; 98:174-80.
85. Haidinger M, Poglitsch M, Geyeregger R et al. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol 2010; 185:3919-31.
86. Jagannath C, Lindsey DR, Dhandayuthapani S, Xu Y, Hunter RL Jr, Eissa NT. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med 2009; 15:267-76.
87. + T cells in NOD mice. Proc Natl Acad Sci U S A 2008; 105:6374-9.
88. + regulatory T cells. J Immunol 2008; 181:6923-33.
89. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188:1359-68.
90. Chen M, Wang YH, Wang Y, Huang L, Sandoval H, Liu YJ, Wang J. Dendritic cell apoptosis in the maintenance of immune tolerance. Science 2006; 311:1160-4.
91. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 2001; 293:306-11.
92. Wallet MA, Sen P, Flores RR et al. MerTK is required for apoptotic cell-induced T cell tolerance. J Exp Med 2008; 205:219-32.
93. Kushwah R, Oliver JR, Zhang J, Siminovitch KA, Hu J. Apoptotic dendritic cells induce tolerance in mice through suppression of dendritic cell maturation and induction of antigen-specific regulatory T cells. J Immunol 2009; 183:7104-18.
94. Fleischmann RM. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 2009; 38:265-80.
95. Sharabi A, Mozes E. Harnessing regulatory T cells for the therapy of lupus and other autoimmune diseases. Immunotherapy 2009; 1:385-401.
96. Leung PS, Dhirapong A, Wu PY, Tao MH. Gene therapy in autoimmune diseases: challenges and opportunities. Autoimmun Rev 2010; 9:170-4.
97. Bach JF. Immunosuppressive therapy of autoimmune diseases. Immunol Today 1993; 14:322-6.
98. Furlan R, Butti E, Pluchino S, Martino G. Gene therapy for autoimmune diseases. Curr Opin Mol Ther 2004; 6:525-36.
99. Dazzi F, van Laar JM, Cope A, Tyndall A. Cell therapy for autoimmune diseases. Arthritis Res Ther 2007; 9:206.
100. Pascual V, Chaussabel D, Banchereau J. A genomic approach to human autoimmune diseases. Annu Rev Immunol 2010; 28:535-71.
101. Bruder D, Westendorf AM, Hansen W et al. On the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes. Diabetes 2005; 54:3395-401.
102. Xiao BG, Huang YM, Link H. Dendritic cell vaccine design: strategies for eliciting peripheral tolerance as therapy of autoimmune diseases. BioDrugs 2003; 17:103-11.
103. Khoury SJ, Gallon L, Chen W et al. Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo. J Exp Med 1995; 182:357-66.
104. Feili-Hariri M, Flores RR, Vasquez AC, Morel PA. Dendritic cell immunotherapy for autoimmune diabetes. Immunol Res 2006; 36:167-73.
105. Ohnmacht C, Pullner A, King SB, Drexler I, Meier S, Brocker T, Voehringer D. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med 2009; 206:549-59.
106. Flotte TR, Ng P, Dylla DE, McCray PB Jr, Wang G, Kolls JK, Hu J. Viral vector-mediated and cell-based therapies for treatment of cystic fibrosis. Mol Ther 2007; 15:229-41.
107. Colella P, Cotugno G, Auricchio A. Ocular gene therapy: current progress and future prospects. Trends Mol Med 2009; 15:23-31.
108. Richardson RM, Varenika V, Forsayeth JR, Bankiewicz KS. Future applications: gene therapy. Neurosurg Clin N Am 2009; 20:205-10.
109. Herrera OB, Golshayan D, Tibbott R, Salcido Ochoa F, James MJ, Marelli-Berg FM, Lechler RI. A novel pathway of alloantigen presentation by dendritic cells. J Immunol 2004; 173:4828-37.
110. Gould DS, Auchincloss H Jr. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today 1999; 20:77-82.
111. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7:610-21.
112. Ali A, Garrovillo M, Jin MX, Hardy MA, Oluwole SF. Major histocompatibility complex class I peptide-pulsed host dendritic cells induce antigen-specific acquired thymic tolerance to islet cells. Transplantation 2000; 69:221-6.
113. Ali A, Garrovillo M, Oluwole OO, Depaz HA, Gopinathan R, Engelstad K, Hardy MA, Oluwole SF. Mechanisms of acquired thymic tolerance: induction of transplant tolerance by adoptive transfer of in vivo alloMHC peptide activated syngeneic T cells. Transplantation 2001; 71:1442-8.
114. Garrovillo M, Ali A, Oluwole SF. Indirect allorecognition in acquired thymic tolerance: induction of donor-specific tolerance to rat cardiac allografts by allopeptide-pulsed host dendritic cells. Transplantation 1999; 68:1827-34.
115. Garrovillo M, Ali AO, DePaz HA, Gopinathan R, Oluwole OO, Hardy MA, Oluwole SF. Regulatory role of the thymic dendritic cells in acquired thymic tolerance: induction of tolerance to cardiac allografts by adoptive transfer of allopeptide-pulsed host thymic dendritic cells. Transplant Proc 2001; 33:149.
116. Oluwole OO, Depaz HA, Gopinathan R, Ali A, Garrovillo M, Jin MX, Hardy MA, Oluwole SF. Indirect allorecognition in acquired thymic tolerance: induction of donor-specific permanent acceptance of rat islets by adoptive transfer of allopeptide-pulsed host myeloid and thymic dendritic cells. Diabetes 2001; 50:1546-52.
117. Mirenda V, Berton I, Read J, Cook T, Smith J, Dorling A, Lechler RI. Modified dendritic cells coexpressing self and allogeneic major histocompatability complex molecules: an efficient way to induce indirect pathway regulation. J Am Soc Nephrol 2004; 15:987-97.
118. Senju S, Matsunaga Y, Fukushima S, Hirata S, Matsuyoshi H, Nishimura Y. Pluripotent stem cell-derived dendritic cells for immunotherapy. Front Biosci (Elite Ed) 2010; 2:1520-7.
119. Nair S, McLaughlin C, Weizer A, Su Z, Boczkowski D, Dannull J, Vieweg J, Gilboa E. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 2003; 171:6275-82.
120. De Vries IJ, Krooshoop DJ, Scharenborg NM et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003; 63:12-7.
121. Lensmar C, Nord M, Gudmundsson GH et al. Decreased pulmonary levels of the anti-inflammatory Clara cell 16kDa protein after induction of airway inflammation in asthmatics. Cell Mol Life Sci 2000; 57:976-81.
122. Katavolos P, Ackerley CA, Viel L, Clark ME, Wen X, Bienzle D. Clara cell secretory protein is reduced in equine recurrent airway obstruction. Vet Pathol 2009; 46:604-13.
123. Plopper CG, Hill LH, Mariassy AT. Ultrastructure of the nonciliated bronchiolar epithelial (Clara) cell of mammalian lung. III. A study of man with comparison of 15 mammalian species. Exp Lung Res 1980; 1:171-80.